Key Points
- Insider sale: Kura Oncology insider Mollie Leoni sold 84,929 shares on June 18 at an average price of $9.82, totaling about $834,003. After the transaction, she still held 182,345 shares, a 31.78% reduction in her position.
- Company snapshot: Kura Oncology opened at $10.36 and has a market cap of about $919.66 million. The stock has traded between $5.45 and $12.49 over the past 52 weeks.
- Analyst outlook and earnings: The company recently beat EPS estimates for the quarter, but revenue came in below expectations and profitability remains deeply negative. Analysts currently view the stock as a Moderate Buy with an average price target of $25.46.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Mollie Leoni sold 84,929 shares of the company's stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Kura Oncology Price Performance
NASDAQ KURA opened at $10.36 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The firm has a market capitalization of $919.66 million, a price-to-earnings ratio of -3.09 and a beta of 0.36. The company has a 50 day simple moving average of $9.44 and a 200-day simple moving average of $9.23. Kura Oncology, Inc. has a 52-week low of $5.45 and a 52-week high of $12.49.
Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. Equities research analysts predict that Kura Oncology, Inc. will post -3.47 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on KURA. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Wall Street Zen raised Kura Oncology from a "strong sell" rating to a "hold" rating in a research report on Saturday, May 16th. Mizuho lowered their target price on Kura Oncology from $30.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 24th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kura Oncology in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average target price of $25.46.
Read Our Latest Analysis on Kura Oncology
Institutional Trading of Kura Oncology
Several large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in shares of Kura Oncology by 214.1% during the 4th quarter. SG Americas Securities LLC now owns 151,715 shares of the company's stock worth $1,576,000 after buying an additional 103,411 shares during the period. UBS Group AG grew its stake in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company's stock valued at $11,014,000 after buying an additional 574,455 shares during the last quarter. Nan Fung Trinity HK Ltd. raised its holdings in Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company's stock worth $10,025,000 after acquiring an additional 734,000 shares during the period. Rhenman & Partners Asset Management AB raised its holdings in Kura Oncology by 96.0% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 490,000 shares of the company's stock worth $4,336,000 after acquiring an additional 240,000 shares during the period. Finally, Moody Aldrich Partners LLC acquired a new position in Kura Oncology during the 4th quarter worth $1,867,000.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
